CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease

European Journal of Immunology

Volumn 42, Issue 11, 2012, Pages 3062-3072

  Doherty, Glen A ^a   Bai, Aiping ^a   Hanidziar, Dusan ^a   Longhi, Maria S ^a   Lawlor, Garrett O ^a   Putheti, Prabhakar ^a   Csizmadia, Eva ^a   Nowak, Martina ^a   Cheifetz, Adam S ^a   Moss, Alan C ^a   Robson, Simon C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD73; Crohn's disease; Ectonucleotidase; Inflammatory bowel disease; T lymphocytes

Indexed keywords

5' NUCLEOTIDASE; CD45RO ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CROHN DISEASE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LAMINA PROPRIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL;

5'-NUCLEOTIDASE; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; GASTROINTESTINAL AGENTS; GPI-LINKED PROTEINS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES, MONONUCLEAR; MUCOUS MEMBRANE; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868095501     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242623     Document Type: Article

References (29)

1. Friedman, D. J., Kunzli, B. M., Rahim, Y. I., Sevigny, J., Berberat, P. O., Enjyoji, K., Csizmadia, E. et al., From the cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 2009. 106: 16788-16793.
2. Louis, N. A., Robinson, A. M., MacManus, C. F., Karhausen, J., Scully, M. and Colgan, S. P., Control of IFN-alphaA by CD73: implications for mucosal inflammation. J. Immunol. 2008. 180: 4246-4255.
3. Atarashi, K., Nishimura, J., Shima, T., Umesaki, Y., Yamamoto, M., Onoue, M., Yagita, H. et al., ATP drives lamina propria T(H)17 cell differentiation. Nature 2008. 455: 808-812.
4. Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J. F. et al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007. 204: 1257-1265.
5. Odashima, M., Bamias, G., Rivera-Nieves, J., Linden, J., Nast, C. C., Moskaluk, C. A., Marini, M. et al., Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005. 129: 26-33.
6. Lappas, C. M., Rieger, J. M. and Linden, J., A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J. Immunol. 2005. 174: 1073-1080.
7. Dwyer, K. M., Hanidziar, D., Putheti, P., Hill, P. A., Pommey, S., McRae, J. L., Winterhalter, A. et al., Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am. J. Transplant. 2010. 10: 2410-2420.
8. Yang, L., Kobie, J. J. and Mosmann, T. R., CD73 and Ly-6A/E distinguish in vivo primed but uncommitted mouse CD4 T cells from type 1 or type 2 effector cells. J. Immunol. 2005. 175: 6458-6464.
9. Sarra, M., Monteleone, I., Stolfi, C., Fantini, M. C., Sileri, P., Sica, G., Tersigni, R. et al., Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm. Bowel. Dis. 2010. 16: 1332-1339.
10. Yang, X. O., Nurieva, R., Martinez, G. J., Kang, H. S., Chung, Y., Pappu, B. P., Shah, B. et al., Molecular antagonism and plasticity of regulatory and inflammatory T-cell programs. Immunity 2008. 29: 44-56.
11. Zhou, Q., Yan, J., Putheti, P., Wu, Y., Sun, X., Toxavidis, V., Tigges, J. et al., Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations. Am. J. Transplant. 2009. 9: 2303-2311.
12. Rybaczyk, L., Rozmiarek, A., Circle, K., Grants, I., Needleman, B., Wunderlich, J. E., Huang, K. et al., New bioinformatics approach to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC. Inflamm. Bowel. Dis. 2009. 15: 971-984.
13. Dwyer, K. M., Deaglio, S., Gao, W., Friedman, D., Strom, T. B. and Robson, S. C., CD39 and control of cellular immune responses. Purinergic. Signal. 2007. 3: 171-180.
14. Fletcher, J. M., Lonergan, R., Costelloe, L., Kinsella, K., Moran, B., O'Farrelly, C., Tubridy, N. et al., CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 2009. 183: 7602-7610.
15. Mills, J. H., Thompson, L. F., Mueller, C., Waickman, A. T., Jalkanen, S., Niemela, J., Airas, L. et al., CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2008. 105: 9325-9330.
16. Resta, R., Yamashita, Y. and Thompson, L. F., Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 1998. 161: 95-109.
17. Alam, M. S., Kurtz, C. C., Rowlett, R. M., Reuter, B. K., Wiznerowicz, E., Das, S., Linden, J. et al., CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J. Infect. Dis. 2009. 199: 494-504.
18. Deaglio, S. and Robson, S. C., Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 2011. 61: 301-332.
19. Totsuka, T., Kanai, T., Nemoto, Y., Tomita, T., Tsuchiya, K., Sakamoto, N., Okamoto, R. et al., Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis. Eur. J. Immunol. 2008. 38: 1275-1286.
20. Beriou, G., Costantino, C. M., Ashley, C. W., Yang, L., Kuchroo, V. K., Baecher-Allan, C. and Hafler, D. A., IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009. 113: 4240-4249.
21. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L. et al., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006. 441: 235-238.
22. Tomita, T., Kanai, T., Fujii, T., Nemoto, Y., Okamoto, R., Tsuchiya, K., Totsuka, T. et al., Continuous generation of colitogenic CD4(+) T cells in persistent colitis. Eur. J. Immunol. 2008. 38: 1264-1274.
23. Nemoto, Y., Kanai, T., Kameyama, K., Shinohara, T., Sakamoto, N., Totsuka, T., Okamoto, R. et al., Long-lived colitogenic CD4+ memory T cells residing outside the intestine participate in the perpetuation of chronic colitis. J. Immunol. 2009. 183: 5059-5068.
24. Tomita, T., Kanai, T., Nemoto, Y., Fujii, T., Nozaki, K., Okamoto, R., Tsuchiya, K. et al., Colitogenic CD4 +effector-memory T cells actively recirculate in chronic colitic mice. Inflamm. Bowel. Dis. 2008. 14: 1630-1640.
25. Naganuma, M., Wiznerowicz, E. B., Lappas, C. M., Linden, J., Worthington, M. T. and Ernst, P. B., Cutting edge: critical role for A2A adenosine receptors in the T-cell-mediated regulation of colitis. J. Immunol. 2006. 177: 2765-2769.
26. Odashima, M., Bamias, G., Rivera-Nieves, J., Linden, J., Nast, C. C., Moskaluk, C. A., Marini, M. et al., Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005. 129: 26-33.
27. Morabito, L., Montesinos, M. C., Schreibman, D. M., Balter, L., Thompson, L. F., Resta, R., Carlin, G. et al., Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 1998. 101: 295-300.
28. Riksen, N. P., Barrera, P., van den Broek, P. H., van Riel, P. L., Smits, P. and Rongen, G. A., Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann. Rheum. Dis. 2006. 65: 465-470.
29. Atreya, I. and Neurath, M. F., Understanding the delayed onset of action of azathioprine in IBD: are we there yet? Gut 2009. 58: 325-326.